Clinical Trials

Several clinical trials evaluate therapeutic monitoring, real-world treatment effectiveness, and registry outcomes in neuroinflammatory and neuromuscular conditions, primarily multiple sclerosis, relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, and spinal muscular atrophy. Sponsored by major pharmaceutical entities including Biogen, Novartis, and Merck Healthcare KGaA, these observational studies encompass actively recruiting and completed cohorts without formally designated interventional phases. These investigations collect real-world data to characterize nationwide patient profiles, monitor therapeutic utilization, and identify predictors of treatment response.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05797740 Recruiting
Multiple Sclerosis
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
2023-08-03 --
NCT05618379 Recruiting
Muscular Atrophy Spinal
Biogen
2023-01-06 --
NCT05266469 Recruiting
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals|Novartis
2022-07-26 --
NCT04997148 Completed
Relapsing-Remitting Multiple Sclerosis
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany|Merck Serono Limited an affiliate of Merck KGaA Darmstadt Germany
2021-08-11 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Dimethyl Trisulfide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an organic trisulfide compound, dimethyl trisulfide functions as a donor of reactive sulfur species and hydrogen sulfide, which modulate cellular redox signaling pathways and mitigate oxidative stress. This modification of cellular bioenergetics and inhibition of pro-inflammatory cascade signaling protects neuronal cell integrity, offering therapeutic relevance in neuroinflammatory and neurodegenerative conditions such as multiple sclerosis and spinal muscular atrophy.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.